Skip to content

Prevalence of Multidrug Resistant Micro-organism Carriage in Patients Undergoing an ERCP in Four Different Countries

Prevalence of Multidrug Resistant Micro-organism Carriage in Patients Undergoing an Endoscopic Retrograde Cholangiopancreatography in Four Different Countries

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05303662
Acronym
PREVENT
Enrollment
1244
Registered
2022-03-31
Start date
2022-01-31
Completion date
2024-12-30
Last updated
2025-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholangiopancreatography, Endoscopic Retrograde, Drug Resistance, Multiple, Bacterial

Keywords

Cholangiopancreatography, Endoscopic Retrograde, Drug Resistance, Multiple, Bacterial, Equipment Contamination, Duodenoscope associated infection

Brief summary

The duodenoscopes currently used for Endoscopic Retrograde Cholangio - and Pancreaticography (ERCP) examinations are reusable and are therefore washed and disinfected after each use. Despite this, these endoscopes sometimes remain contaminated with bacteria. Several reports of outbreaks linked to contaminated duodenoscopes have been published worldwide. Recently, the Food and Drug Administration (FDA) advised manufacturers and health care professionals to transition away from fixed endcap duodenoscopes and instead focus more on the use of duodenoscopes with disposable components or fully disposable duodenoscopes. Single-use endoscopes have been developed, but they are not yet widely used, partly because of the extra costs that these endoscopes add to the examination. A possible interim solution, is to only use these disposable endoscopes in patients who carry multi-resistant bacteria in order to prevent the spread of these bacteria. For this, it is important to know how many people who undergo an ERCP carry multi-resistant bacteria. The primary objective of this study is to measure the prevalence of multi-resistant bacteria in patients undergoing ERCP in four different countries: India, the Netherlands, Italy and the United States. In the Netherlands, some secondary outcomes will be investigated with regard to the prevalence of duodenoscope contamination, the risk of bacterial transmission via a contaminated duodenoscope and the presence of multi-resistant bacteria in the duodenum.

Interventions

DIAGNOSTIC_TESTMultidrug-Resistant Organisms (MDRO) testing through rectal and oral/nasal swabs

Pooled throat/nose sample and a rectal sample is taken prior to the ERCP

DIAGNOSTIC_TESTMDRO-testing duodenal aspirate

Duodenal aspirate is collected from the duodenum, diluted and undiluted. Then cultured for presence of MDRO's

DIAGNOSTIC_TESTMicrobiome through rectal swab

An rectal swab is collected for microbiome purposes

DIAGNOSTIC_TESTMicrobiome testing duodenal aspirate

Duodenal aspirate is collected from the duodenum, diluted and undiluted for microbiome analysis

Sponsors

Boston Scientific Corporation
CollaboratorINDUSTRY
Marco J. Bruno
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* The subject is planned to undergo an ERCP procedure, either through an outpatient department or an inpatient department * The subject is capable to understand the information required to give informed consent

Exclusion criteria

* In case the inclusion criteria were not met

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of multidrug resistant micro-organism carriage in patients undergoing an ERCP in four different countries1 weekPrevalence (as a percentage) of Methicillin-resistant Staphylococcus aureus (MRSA) in nasal or throat swabs, along with rectal carriage rates of Extended Spectrum Beta-Lactamase (ESBL), Vancomycin-resistant Enterococci (VRE), Carbapenem-resistant Enterobacterales (CRE), Carbapenemase-Producing Pseudomonas aeruginosa (CPP), and resistant Acinetobacter among ERCP patients in India, the Netherlands, Italy, and the United States.

Secondary

MeasureTime frameDescription
Prevalence of multidrug resistant micro-organism carriage in the duodenum of patients undergoing ERCP compared to the rectum1 weekPrevalence (as a percentage) of duodenal carriage of MRSA, ESBL, VRE, CRE, CPP, and resistant Acinetobacter among ERCP patients in both India and the Netherlands.
Differences of rectal microbiome between ERCP patients carrying MDRO compared to patients without MDRO1 weekSequencing data analysis, such as 16S rRNA gene sequencing, will be used to assess the overall composition of the rectal microbiome. This will involve the identification of various bacterial taxa present in the samples and determining their relative proportions. The results will provide information on the broader microbial community composition. These results will be compared between ERCP patients carrying MDRO and those without MDRO to investigate differences in both specific bacterial species' abundance and overall microbiome composition.
Prevalence of duodenoscope-associated infections and colonizations6 monthsComparison of isolates form duodenoscope cultures with isolates from clinical cultures from patients treated with a contaminated duodenoscope in order to detect transmission.
Differences of duodenal microbiome between ERCP patients carrying MDRO compared to patients without MDRO1 weekSequencing data analysis, such as 16S rRNA gene sequencing, will be used to assess the overall composition of the duodenal microbiome. This will involve the identification of various bacterial taxa present in the samples and determining their relative proportions. The results will provide information on the broader microbial community composition. These results will be compared between ERCP patients carrying MDRO and those without MDRO to investigate differences in both specific bacterial species' abundance and overall microbiome composition.

Countries

India, Italy, Netherlands, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026